RxDoctor Payments DataLook up a doctor →

Judy Wang, MD

Medical Oncology · Sarasota, FLNPI 1053554717

Payments from drug & device makers

$9,839,905in general payments, 2019–2025

Across 2,842 payments — averaging $3462.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$2.1M
  • Beigene, Ltd.$1.4M
  • GSK$1.3M
  • Astellas Pharma Inc$947K
  • AstraZeneca$557K
  • Beigene USA, Inc.$385K
  • plus $3.2M from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck171$2,086,100
Beigene, Ltd.521$1,390,239
GSK299$1,314,059
Astellas Pharma Inc457$946,897
AstraZeneca(2 entities)116$556,810
Beigene USA, Inc.182$385,052
Pfizer94$375,223
Biontech SE54$359,749
Astrazeneca UK Limited14$284,707
Tesaro, Inc.31$243,137
Astrazeneca AB18$222,217
AbbVie91$184,156
Acerta Pharma LLC1$176,318
Boehringer Ingelheim International GmbH93$160,672
Day One Biopharmaceuticals70$151,682
Stemline Therapeutics Inc.56$149,052
Boehringer Ingelheim25$117,534
Eli Lilly2$107,652
Sanofi US Services Inc.45$87,977
Beone Medicines Ltd.32$71,962
Synthorx Inc.25$68,895
Immunogen, Inc.21$65,964
Takeda Pharmaceuticals U.S.A., Inc.34$63,179
Janssen Research & Development, LLC25$52,711
Taiho Oncology, Inc.25$46,086
Daiichi Sankyo Inc.16$46,067
E.r. Squibb & Sons, L.L.C.29$41,392
Coherus Oncology, Inc.3$30,285
Bayer8$23,740
Boehringer Ingelheim Pharma GmbH & Co.kg3$9,783
Boehringer Ingelheim Espana S.A.11$7,796
Eisai Inc.15$7,755
Lilly USA, LLC30$531
Genentech, Inc.1$425
Johnson & Johnson(2 entities)26$365
Seagen Inc.23$333
Incyte Corporation18$302
Bristol Myers Squibb17$283
Array Biopharma Inc14$254
Sanofi11$178
Abbott1$174
Heron Therapeutics, Inc.3$160
Gilead(2 entities)8$154
Novartis5$144
Astellas Pharma US Inc7$131
Covidien LP1$125
Pharmacyclics LLC, An Abbvie Company6$125
Amgen8$121
Jazz Pharmaceuticals Inc.8$115
Mirati Therapeutics, Inc.5$104
Exelixis Inc.6$84
Foundation Medicine, Inc.1$78
Karyopharm Therapeutics Inc.4$61
Puma Biotechnology, Inc.4$57
Genentech USA, Inc.4$55
Regeneron Healthcare Solutions, Inc.3$50
Sumitomo Pharma America, Inc.3$49
EMD Serono, Inc.3$49
Dova Pharmaceuticals3$49
Adaptive Biotechnologies Corporation1$47

How this compares

$9,839,905 in reported general payments places this provider in the 95th percentile of 507 medical oncology providers in Florida.

See all medical oncology providers in Florida →

Medicare billing

Part B allowed, 2024
$217,727
Medicare patients
156
Services billed
24,746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Sarasota

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →